NURIX THERAPEUTICS INC's ticker is NRIX and the CUSIP is 67080M103. A total of 120 filers reported holding NURIX THERAPEUTICS INC in Q3 2022. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $628,069 | -21.3% | 79,907 | 0.0% | 0.00% | -50.0% |
| Q2 2023 | $798,271 | +12.5% | 79,907 | 0.0% | 0.00% | 0.0% |
| Q1 2023 | $709,574 | -19.1% | 79,907 | 0.0% | 0.00% | 0.0% |
| Q4 2022 | $877,379 | -22.6% | 79,907 | -8.1% | 0.00% | -33.3% |
| Q3 2022 | $1,133,000 | +5.5% | 86,967 | +2.6% | 0.00% | 0.0% |
| Q2 2022 | $1,074,000 | -9.6% | 84,797 | 0.0% | 0.00% | +50.0% |
| Q1 2022 | $1,188,000 | +736.6% | 84,797 | +1634.1% | 0.00% | – |
| Q4 2021 | $142,000 | +491.7% | 4,890 | +512.0% | 0.00% | – |
| Q3 2021 | $24,000 | +14.3% | 799 | 0.0% | 0.00% | – |
| Q2 2021 | $21,000 | -16.0% | 799 | 0.0% | 0.00% | – |
| Q1 2021 | $25,000 | -3.8% | 799 | 0.0% | 0.00% | – |
| Q4 2020 | $26,000 | -7.1% | 799 | 0.0% | 0.00% | – |
| Q3 2020 | $28,000 | – | 799 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Bain Capital Life Sciences Investors, LLC | 1,822,883 | $14,327,860 | 1.60% |
| DAFNA Capital Management LLC | 556,695 | $4,375,623 | 1.36% |
| Redmile Group, LLC | 2,848,827 | $22,391,780 | 1.06% |
| Deep Track Capital, LP | 2,997,830 | $23,562,944 | 0.91% |
| WestHill Financial Advisors, Inc. | 283,333 | $2,226,997 | 0.65% |
| Soleus Capital Management, L.P. | 814,000 | $6,398,040 | 0.59% |
| Affinity Asset Advisors, LLC | 250,000 | $1,965,000 | 0.55% |
| Boxer Capital, LLC | 1,224,892 | $9,627,651 | 0.51% |
| AtonRa Partners | 24,227 | $190,424 | 0.40% |
| WASATCH ADVISORS LP | 3,564,616 | $28,017,882 | 0.18% |